These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34863304)

  • 21. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
    van den Berg K; Glatt TN; Vermeulen M; Little F; Swanevelder R; Barrett C; Court R; Bremer M; Nyoni C; Swarts A; Mmenu C; Crede T; Kritzinger G; Naude J; Szymanski P; Cowley J; Moyo-Gwete T; Moore PL; Black J; Singh J; Bhiman JN; Baijnath P; Mody P; Malherbe J; Potgieter S; van Vuuren C; Maasdorp S; Wilkinson RJ; Louw VJ; Wasserman S
    Sci Rep; 2022 Feb; 12(1):2552. PubMed ID: 35169169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Convalescent Plasma for High-Risk Outpatients with Covid-19.
    Korley FK; Durkalski-Mauldin V; Yeatts SD; Schulman K; Davenport RD; Dumont LJ; El Kassar N; Foster LD; Hah JM; Jaiswal S; Kaplan A; Lowell E; McDyer JF; Quinn J; Triulzi DJ; Van Huysen C; Stevenson VLW; Yadav K; Jones CW; Kea B; Burnett A; Reynolds JC; Greineder CF; Haas NL; Beiser DG; Silbergleit R; Barsan W; Callaway CW;
    N Engl J Med; 2021 Nov; 385(21):1951-1960. PubMed ID: 34407339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
    Brox R; Achenbach S; Hackstein H
    Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
    Axfors C; Janiaud P; Schmitt AM; Van't Hooft J; Smith ER; Haber NA; Abayomi A; Abduljalil M; Abdulrahman A; Acosta-Ampudia Y; Aguilar-Guisado M; Al-Beidh F; Alejandria MM; Alfonso RN; Ali M; AlQahtani M; AlZamrooni A; Anaya JM; Ang MAC; Aomar IF; Argumanis LE; Averyanov A; Baklaushev VP; Balionis O; Benfield T; Berry S; Birocco N; Bonifacio LB; Bowen AC; Bown A; Cabello-Gutierrez C; Camacho B; Camacho-Ortiz A; Campbell-Lee S; Cao DH; Cardesa A; Carnate JM; Castillo GJJ; Cavallo R; Chowdhury FR; Chowdhury FUH; Ciccone G; Cingolani A; Climacosa FMM; Compernolle V; Cortez CFN; Costa Neto A; D'Antico S; Daly J; Danielle F; Davis JS; De Rosa FG; Denholm JT; Denkinger CM; Desmecht D; Díaz-Coronado JC; Díaz Ponce-Medrano JA; Donneau AF; Dumagay TE; Dunachie S; Dungog CC; Erinoso O; Escasa IMS; Estcourt LJ; Evans A; Evasan ALM; Fareli CJ; Fernandez-Sanchez V; Galassi C; Gallo JE; Garcia PJ; Garcia PL; Garcia JA; Garigliany M; Garza-Gonzalez E; Gauiran DTV; Gaviria García PA; Giron-Gonzalez JA; Gómez-Almaguer D; Gordon AC; Gothot A; Grass Guaqueta JS; Green C; Grimaldi D; Hammond NE; Harvala H; Heralde FM; Herrick J; Higgins AM; Hills TE; Hines J; Holm K; Hoque A; Hoste E; Ignacio JM; Ivanov AV; Janssen M; Jennings JH; Jha V; King RAN; Kjeldsen-Kragh J; Klenerman P; Kotecha A; Krapp F; Labanca L; Laing E; Landin-Olsson M; Laterre PF; Lim LL; Lim J; Ljungquist O; Llaca-Díaz JM; López-Robles C; López-Cárdenas S; Lopez-Plaza I; Lucero JAC; Lundgren M; Macías J; Maganito SC; Malundo AFG; Manrique RD; Manzini PM; Marcos M; Marquez I; Martínez-Marcos FJ; Mata AM; McArthur CJ; McQuilten ZK; McVerry BJ; Menon DK; Meyfroidt G; Mirasol MAL; Misset B; Molton JS; Mondragon AV; Monsalve DM; Moradi Choghakabodi P; Morpeth SC; Mouncey PR; Moutschen M; Müller-Tidow C; Murphy E; Najdovski T; Nichol AD; Nielsen H; Novak RM; O'Sullivan MVN; Olalla J; Osibogun A; Osikomaiya B; Oyonarte S; Pardo-Oviedo JM; Patel MC; Paterson DL; Peña-Perez CA; Perez-Calatayud AA; Pérez-Alba E; Perkina A; Perry N; Pouladzadeh M; Poyato I; Price DJ; Quero AKH; Rahman MM; Rahman MS; Ramesh M; Ramírez-Santana C; Rasmussen M; Rees MA; Rego E; Roberts JA; Roberts DJ; Rodríguez Y; Rodríguez-Baño J; Rogers BA; Rojas M; Romero A; Rowan KM; Saccona F; Safdarian M; Santos MCM; Sasadeusz J; Scozzari G; Shankar-Hari M; Sharma G; Snelling T; Soto A; Tagayuna PY; Tang A; Tatem G; Teofili L; Tong SYC; Turgeon AF; Veloso JD; Venkatesh B; Ventura-Enriquez Y; Webb SA; Wiese L; Wikén C; Wood EM; Yusubalieva GM; Zacharowski K; Zarychanski R; Khanna N; Moher D; Goodman SN; Ioannidis JPA; Hemkens LG
    BMC Infect Dis; 2021 Nov; 21(1):1170. PubMed ID: 34800996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
    Agarwal A; Mukherjee A; Kumar G; Chatterjee P; Bhatnagar T; Malhotra P;
    BMJ; 2020 Oct; 371():m3939. PubMed ID: 33093056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
    Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
    J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
    Al-Tawfiq JA; Arabi Y
    Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis.
    Jorda A; Kussmann M; Kolenchery N; Siller-Matula JM; Zeitlinger M; Jilma B; Gelbenegger G
    Front Immunol; 2022; 13():817829. PubMed ID: 35197981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Convalescent Plasma in Patients With Covid-19 in Intensive Care Unit.
    Bereanu A; Crisan O; Constantin AM; Cainap S; Cainap C; Dragulescu R; Bereanu R; Vintila B; Roman C; Sava M
    In Vivo; 2022; 36(3):1342-1348. PubMed ID: 35478150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
    Senefeld JW; Johnson PW; Kunze KL; Bloch EM; van Helmond N; Golafshar MA; Klassen SA; Klompas AM; Sexton MA; Diaz Soto JC; Grossman BJ; Tobian AAR; Goel R; Wiggins CC; Bruno KA; van Buskirk CM; Stubbs JR; Winters JL; Casadevall A; Paneth NS; Shaz BH; Petersen MM; Sachais BS; Buras MR; Wieczorek MA; Russoniello B; Dumont LJ; Baker SE; Vassallo RR; Shepherd JRA; Young PP; Verdun NC; Marks P; Haley NR; Rea RF; Katz L; Herasevich V; Waxman DA; Whelan ER; Bergman A; Clayburn AJ; Grabowski MK; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Buchholtz ZA; Pletsch MC; Wright K; Greenshields JT; Joyner MJ; Wright RS; Carter RE; Fairweather D
    PLoS Med; 2021 Dec; 18(12):e1003872. PubMed ID: 34928960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).
    Bajpai M; Maheshwari A; Dogra V; Kumar S; Gupta E; Kale P; Saluja V; Thomas SS; Trehanpati N; Bihari C; Agarwal R; Bharti P; Shankar P; Hussain J; Chhabra K; Gupta A; Narayanan A; Agarwal S; Jain S; Bhardwaj A; Kumar G; Yadav BK; Sarin SK
    BMJ Open; 2022 Apr; 12(4):e055189. PubMed ID: 35387813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.
    Ljungquist O; Lundgren M; Iliachenko E; Månsson F; Böttiger B; Landin-Olsson M; Wikén C; Rosendal E; Överby AK; Wigren BJ; Forsell MNE; Kjeldsen-Kragh J; Rasmussen M; Kahn F; Holm K
    Infect Dis (Lond); 2022 Apr; 54(4):283-291. PubMed ID: 34878955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.